Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 17

1.

Antiepileptic drugs' tolerability and safety - a systematic review and meta-analysis of adverse effects in dogs.

Charalambous M, Shivapour SK, Brodbelt DC, Volk HA.

BMC Vet Res. 2016 May 21;12(1):79. doi: 10.1186/s12917-016-0703-y.

2.

What do patients and the public know about clinical practice guidelines and what do they want from them? A qualitative study.

Fearns N, Kelly J, Callaghan M, Graham K, Loudon K, Harbour R, Santesso N, McFarlane E, Thornton J, Treweek S.

BMC Health Serv Res. 2016 Feb 24;16(1):74. doi: 10.1186/s12913-016-1319-4.

3.

Evaluating Harms in the Assessment of Net Benefit: A Framework for Newborn Screening Condition Review.

Goldenberg AJ, Comeau AM, Grosse SD, Tanksley S, Prosser LA, Ojodu J, Botkin JR, Kemper AR, Green NS.

Matern Child Health J. 2016 Mar;20(3):693-700. doi: 10.1007/s10995-015-1869-9.

PMID:
26833040
4.

Assessing the detection, reporting and investigation of adverse events in clinical trial protocols implemented in Cameroon: a documentary review of clinical trial protocols.

Ebile AW, Ateudjieu J, Yakum MN, Djuidje MN, Watcho P.

BMC Med Ethics. 2015 Sep 29;16(1):67. doi: 10.1186/s12910-015-0061-5.

5.

Comparison of treatment effect estimates for pharmacological randomized controlled trials enrolling older adults only and those including adults: a meta-epidemiological study.

Seegers V, Trinquart L, Boutron I, Ravaud P.

PLoS One. 2013 May 28;8(5):e63677. doi: 10.1371/journal.pone.0063677. Print 2013.

6.

Sub-lingual immunotherapy: world allergy organization position paper 2009.

Canonica GW, Bousquet J, Casale T, Lockey RF, Baena-Cagnani CE, Pawankar R, Potter PC, Bousquet PJ, Cox LS, Durham SR, Nelson HS, Passalacqua G, Ryan DP, Brozek JL, Compalati E, Dahl R, Delgado L, van Wijk RG, Gower RG, Ledford DK, Filho NR, Valovirta EJ, Yusuf OM, Zuberbier T.

World Allergy Organ J. 2009 Nov;2(11):233-81. doi: 10.1097/WOX.0b013e3181c6c379. Epub 2009 Nov 19. No abstract available.

7.

Developing clinical practice guidelines: types of evidence and outcomes; values and economics, synthesis, grading, and presentation and deriving recommendations.

Woolf S, Sch√ľnemann HJ, Eccles MP, Grimshaw JM, Shekelle P.

Implement Sci. 2012 Jul 4;7:61. doi: 10.1186/1748-5908-7-61.

8.

Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview.

Golder S, Loke YK, Bland M.

PLoS Med. 2011 May;8(5):e1001026. doi: 10.1371/journal.pmed.1001026. Epub 2011 May 3. Review.

9.

Room for improvement? A survey of the methods used in systematic reviews of adverse effects.

Golder S, Loke Y, McIntosh HM.

BMC Med Res Methodol. 2006 Jan 27;6:3.

10.

Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data.

Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC.

BMJ. 2005 Oct 8;331(7520):810. Epub 2005 Sep 12. Review.

11.

Assessing harmful effects in systematic reviews.

McIntosh HM, Woolacott NF, Bagnall AM.

BMC Med Res Methodol. 2004 Jul 19;4:19.

12.

Collecting and sharing information about harms.

Pirmohamed M, Darbyshire J.

BMJ. 2004 Jul 3;329(7456):6-7. No abstract available.

13.

Benefits and harms of drug treatments.

Vandenbroucke JP.

BMJ. 2004 Jul 3;329(7456):2-3. No abstract available.

14.

Synthesising licensing data to assess drug safety.

McPherson K, Hemminki E.

BMJ. 2004 Feb 28;328(7438):518-20. Review. No abstract available.

15.

How to spot bias and other potential problems in randomised controlled trials.

Lewis SC, Warlow CP.

J Neurol Neurosurg Psychiatry. 2004 Feb;75(2):181-7. No abstract available.

16.
17.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk